Patent US4164560A successfully refreshed from Google Patents.
US4164560A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Systems for the controlled release of macromolecules
Assignee: Boston Children's Hospital
•
Filing: 1977-01-05
•
Granted: 1979-08-14
•
Expires: 1997-01-05
Abstract
Abstract Delivery systems manufactured in the form of polymeric compositions for the controlled delivery of macromolecules to environments of use are disclosed. The systems are characterized as two-phase compositions comprising a phase formed of an insoluble polymeric matrix having limited water sorptivity containing in admixture therein an interpenetrating phase formed of a particulate hydrophilic water swellable, biologically active macromolecular material.
Inventors
- 👤 Moses J. Folkman
- 👤 Robert S. Langer, Jr.
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 10:01
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/14; A61K9/16; A61K9/1605; A61K9/1629; A61K9/1635; A61K9/0012; A61K9/0048; A61K9/0051; A61K9/20; A61K9/2004; A61K9/2022; A61K9/2027
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
128 words
A therapeutic system for the continuous and controlled administration of insulin, said system being in the form of a body which is sized and shaped for placement in the environment of use, comprising a two-phase composition of: (a) a first phase comprising a biocompatible, plastically deformable, hydrophobic matrix having an aqueous fluid sorptivity not greater than 50% by weight, of ethylene-vinyl ester copolymer of the general formula: ##STR2## wherein R is a member selected from the group consisting of hydrogen, lower alkyl of 1 to 7 carbons and phenyl, the polymer being insoluble in the environment of use, substantially impermeable to diffusion therethrough of insulin, and containing in admixture therewith; (b) a second phase comprising from about 3 to 90 parts by weight of agglomerated particles of insulin.
Claim 2
Dependent Claim
128 words
A therapeutic system for the continuous and controlled administration of insulin, said system being in the form of a body which is sized and shaped for placement in the environment of use, comprising a two-phase composition of: (a) a first phase comprising a biocompatible, plastically deformable, hydrophobic matrix having an aqueous fluid sorptivity not greater than 50% by weight, of ethylene-vinyl ester copolymer of the general formula: ##STR2## wherein R is a member selected from the group consisting of hydrogen, lower alkyl of 1 to 7 carbons and phenyl, the polymer being insoluble in the environment of use, substantially impermeable to diffusion therethrough of insulin, and containing in admixture therewith; (b) a second phase comprising from about 3 to 90 parts by weight of agglomerated particles of insulin.
Claim 3
Dependent Claim
24 words
The therapeutic system for the administration of insulin according to claim 1, wherein the insulin is substantially continuous and homogenous with said matrix phase.
Claim 4
Dependent Claim
20 words
The therapeutic system for the administration of insulin according to claim 1 wherein the environment is a warm blooded animal.
Claim 5
Dependent Claim
31 words
The therapeutic system for the administration of insulin according to claim 1, wherein the aqueous fluid is a member selected from the group consisting of water, saline, buffers and biological fluids.
Claim 6
Dependent Claim
29 words
The therapeutic system for the administration of insulin according to claim 1, wherein the system comprises from 3 to 90 parts insulin to 97 to 10 parts of matrix.
Claim 7
Dependent Claim
35 words
The therapeutic system for the administration of insulin according to claim 1, wherein the agglomerate comprises a plurality of clusters of insulin molecules that form a network of substantially contiguous particles in the first phase.
Claim 8
Dependent Claim
24 words
The therapeutic system for the administration of insulin according to claim 1, wherein the second phase is an interpenetrating phase within the first phase.
Claim 9
Dependent Claim
26 words
The therapeutic system for the administration of insulin according to claim 5, wherein the total system contains from 25 to 80 parts by weight of insulin.
Claim 10
Dependent Claim
47 words
The therapeutic system for the administration of insulin according to claim 1, wherein the copolymer has a melt index of 0.5 to 100 grams per 10 minutes, a density of 0.920 to 1.00 and a frequency of acyl groups on the ethylene backbone of 1/70 to 1/8.
Claim 11
Dependent Claim
20 words
The therapeutic system for the administration of insulin according to claim 1, wherein the polymeric matrix is ethylene-vinyl acetate copolymer.
Claim 12
Dependent Claim
28 words
The therapeutic system for the administration of insulin according to claim 1, wherein R is methyl and the copolymer has a fluid sorptivity of from 0.015 to 0.67%.
Claim 13
Dependent Claim
23 words
The therapeutic system for the administration of insulin according to claim 1, wherein the two-phase composition is coated with a film of polymer.
References Cited (Backward Citations)
US3880991A
Cited
US3854480A
Cited
US4069307A
Cited
GB1388580A
Cited
US3957740A
Cited
US3903880A
Cited
US4016251A
Cited
GB1443662A
Cited
US4052505A
Cited
US4057619A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1982-08-13 | 1983-02-12 | 1983-08-14 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1986-08-13 | 1987-02-12 | 1987-08-14 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1990-08-13 | 1991-02-12 | 1991-08-14 | $7700.00 | Window Closed / Lapsed |